03819nam a22005057a 4500
171017s20182018 xxu||||| |||| 00| 0 eng d
1388-9842
Ovid MEDLINE(R)
28980368
Similar clinical benefits from below-target and target dose enalapril in patients with heart failure in the SOLVD Treatment trial.
European Journal of Heart Failure. 20(2):359-369, 2018 02.
Eur J Heart Fail. 20(2):359-369, 2018 02.
European journal of heart failure
2018
FY2018
2017-10-17
AIMS: To examine associations of below-target and target dose of enalapril, an angiotensin-converting enzyme (ACE) inhibitor, with outcomes in patients with heart failure and reduced ejection fraction (HFrEF) in the Studies of Left Ventricular Dysfunction (SOLVD) Treatment trial.
CONCLUSION: In patients with HFrEF, the clinical benefits of ACE inhibitors appear to be similar at both below-target and target doses. Copyright (c) 2017 The Authors. European Journal of Heart Failure (c) 2017 European Society of Cardiology.
METHODS AND RESULTS: Two thousand five hundred and sixty-nine patients with HFrEF (ejection fraction <=35%) were randomized to below-target (5-10 mg/day) dose placebo (n = 1284) or enalapril (n = 1285). One month post-randomization, blind up-titration to target (20 mg/day) dose was attempted for both study drugs in 2458 patients. Among the 1444 patients who achieved dose up-titration (placebo, n=748; enalapril, n=696; mean dose for both groups, 20.0 mg/day), target dose enalapril (vs. target dose placebo) was associated with a 9% absolute lower risk of the combined endpoint of heart failure hospitalization or all-cause mortality [adjusted hazard ratio (HR) 0.70; 95% confidence interval (CI) 0.60-0.81; P < 0.001] during 4 years of follow-up. Among the 1014 patients who could not achieve target dose (placebo, n=486; enalapril, n=528; mean dose for both groups, 8.8 mg/day), below-target dose enalapril (vs. below-target dose placebo) was associated with a 12% absolute lower risk of the combined endpoint of heart failure hospitalization or all-cause mortality (adjusted HR 0.68; 95% CI 0.57-0.81; P < 0.001). Among the 1224 patients receiving enalapril, target (vs. below-target) dose had no association with the combined endpoint of heart failure hospitalization or all-cause mortality (adjusted HR 1.04; 95% CI 0.87-1.23; P = 0.695).
English
*Enalapril/ad [Administration & Dosage]
*Heart Failure/dt [Drug Therapy]
*Stroke Volume/de [Drug Effects]
Angiotensin-Converting Enzyme Inhibitors/ad [Administration & Dosage]
Canada/ep [Epidemiology]
Cause of Death/td [Trends]
Dose-Response Relationship, Drug
Double-Blind Method
Europe/ep [Epidemiology]
Follow-Up Studies
Heart Failure/mo [Mortality]
Heart Failure/pp [Physiopathology]
Humans
Stroke Volume/ph [Physiology]
Survival Rate/td [Trends]
Treatment Outcome
United States/ep [Epidemiology]
MedStar Heart & Vascular Institute
Journal Article
Dooley, Daniel J
Lam, Phillip H
Aban IB, Adamopoulos C, Ahmed A, Allman RM, Anker SD, Aronow WS, Arundel C, Bhatt DL, Blackman MR, Butler J, Deedwania P, Dooley DJ, Filippatos GS, Fletcher RD, Fonarow GC, Forman DE, Kanonidis IE, Lam PH, Patel K, Pitt B, White M
https://dx.doi.org/10.1002/ejhf.937
https://dx.doi.org/10.1002/ejhf.937
ART
Article
0
0
0
0
Article
authcat
authcat
2017-10-17
0
28980368
28980368
2017-10-17
2017-10-17
ART
2767
2767